TPG Advisors’s AbbVie ABBV Stock Holding History

TPG Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$549K	Buy	2,181 +50	+2%	+$10.8K	0.3%	61
2026 Q1	$463K	Hold	2,131	–	–	0.29%	62
2025 Q4	$487K	Hold	2,131	–	–	0.3%	56
2025 Q3	$493K	Hold	2,131	–	–	0.32%	51
2025 Q2	$396K	Hold	2,131	–	–	0.29%	57
2025 Q1	$446K	Hold	2,131	–	–	0.35%	50
2024 Q4	$379K	Hold	2,131	–	–	0.3%	53
2024 Q3	$421K	Hold	2,131	–	–	0.33%	51
2024 Q2	$366K	Buy	+2,131	New	+$353K	0.31%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TPG Advisors's ABBV Position: Q2 2026 in Review

TPG Advisors increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $10.8K and bringing the position to 2,181 shares worth $549K. The position accounts for 0.3% of the portfolio, ranked #61.

TPG Advisors first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

TPG Advisors held 2,181 shares of AbbVie worth $549K as of Q2 2026.
TPG Advisors bought 50 AbbVie shares in Q2 2026, an estimated $10.8K.
AbbVie made up 0.3% of TPG Advisors's portfolio in Q2 2026, its #61 holding.
TPG Advisors first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TPG Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.